Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

CEO Drew Hykes attributes Q4's robust revenue growth to heal...

CEO Drew Hykes attributes Q4's robust revenue growth to healthy VTE procedure volumes, emerging therapies' traction, and strong international performance. He also highlights progress across all RCTs and the U.S. launch of LimFlow, emphasizing commitment to strong growth and operating profitability.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more
Translate
Report
2961 Views
Comment
Sign in to post a comment
    avatar
    Moomoo AI Official Account
    Your AI assistant for discovering investment opportunities.
    3219Followers
    0Following
    7986Visitors
    Follow